Citation: Kumar V, Hertz M, Agro A and Byrne AJ (2023) Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis. Front. Immunol. 14:1260503. doi: 10.3389/fimmu.2023.1260503 Chronic tissue inflammation often results in fibrosis characterized by the accumulation of extracellular matrix components remodeling normal tissue architecture and function. Recent studies have suggested common immune mechanisms despite […]
Category: Fibrosis
September is Pulmonary Fibrosis (PF) Awareness Month
September is Pulmonary Fibrosis (PF) Awareness Month. During this month, health charities, research institutes and support groups around the world provide information about Pulmonary Fibrosis. Pulmonary fibrosis is a progressive, incurable disease that affects the tissues in the lungs resulting in lung scarring. Overtime, this leads to a decline in lung function. Sufferers will notice […]
Exercise training in idiopathic pulmonary fibrosis: is it of benefit?
Abstract Exercise is a well-documented safe and effective intervention for prevention and rehabilitation of chronic diseases. Idiopathic pulmonary fibrosis (IPF) is a chronic deadly lung disease associated with severe signs and symptoms, exercise intolerance, diminished quality of life and poor prognosis. In the short term, supervised exercise training programmes have demonstrated clinical benefits in improving […]
Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosisand type 2 diabetes mellitus: a national claims‑based cohort analysis
Abstract BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high morbidity and limited treatment options. Type 2 diabetes mellitus (T2DM) is a common comorbid illness among patients with IPF and is often treated with metformin, the first-line agent in the management of T2DM. There is growing evidence demonstrating metformin’s anti-fibrotic properties; however, […]
TIPAL
TIPAL: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole, a randomised placebo-controlled multi-centre clinical trial The TIPAL research study is focusing on treating idiopathic pulmonary fibrosis (IPF) with the addition of lansoprazole. Lansoprazole reduces the amount of acid your stomach makes. It’s used for indigestion, heartburn, acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is […]
Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
Abstract The mitochondrial calcium uniporter (MCU) regulates metabolic reprogramming in lung macrophages and the progression of pulmonary fibrosis. Fibrosis progression is associated with apoptosis resistance in lung macrophages; however, the mechanism(s) by which apoptosis resistance occurs is poorly understood. Here, we found a marked increase in mitochondrial B-cell lymphoma-2 (Bcl-2) in lung macrophages from subjects […]